CA-ILLUMINA-VENTURES
4.8.2022 14:02:04 CEST | Business Wire | Press release
Illumina Ventures , an independently-managed, healthcare-focused venture firm in a strategic partnership with Illumina (NASDAQ: ILMN) today announced the addition of four new members to its European team. Arnaud Autret, PhD, MSc, will be Principal and Head of European Operations, William Byrne, PhD, be an Associate – Europe, and Ronan Byrne and Ivan Coulter, PhD, BSc, will serve as Venture Advisors – Europe.
“We are already supporting some great companies in Ireland, France and the UK. The addition of Arnaud, William, Ronan and Ivan to our team will enable us build upon our successes and pursue even more ambitious genomics-focused projects in Europe,” said Nick Naclerio, PhD, Illumina Ventures Founding Partner.
Arnaud brings more than 15 years of financial and investment experience in the life sciences and biopharmaceutical industries, as well as scientific knowledge, to his new position. Before joining the Company, Arnaud was Investment Director in the biotechnology team of M Ventures in Amsterdam, which is the corporate venture capital arm of Merck KGaA. Previously, he worked as the Senior Associate in the Life Sciences team at Seventure Partners in Paris, as well as a senior financial auditor in the healthcare business unit at KPMG, also in Paris. Arnaud completed his post-doctoral work in oncology at the Trinity College Dublin after receiving his PhD in immunology from the Pasteur Institute in Paris. Arnaud also holds a MSc in finance from ESCP Business School, in Paris. Arnaud is based in Amsterdam.
Before joining Illumina Ventures, William was Head of Biotechnology at NEOM, a futuristic megacity that will be located in Saudi Arabia and rely on renewable energy and new technology for sustainable living. William led the efforts to establish NEOM as a global biotech hub with a focus on precision medicine. Previously, he worked as a consultant in the healthcare and life sciences industries providing clients located in the Middle East and Europe with investment, research, go-to-market and product launch strategies. William earned a PhD in tumor immunology and a Bachelor of Pharmacy degree at University College Cork in Ireland. He also holds a Master of Business Administration degree from INSEAD in France. William is based in Cork.
As a highly experienced CEO, Ronan has built and led several companies over his career that he later sold to multinational companies. Over the last decade, he has focused his efforts on the commercialization of innovations in the life sciences industry. He was CEO of ClearSight Innovations (Ophthalmic Diagnostic technologies) which sold to an industry leader and is currently the CEO and Co-founder of Pharma Latch in Dublin, which is developing a revolutionary intradermal delivery technology for drugs, vaccines, and a range of immunotherapies; he is also Business Mentor at Enterprise Ireland. Ronan received both a Master of Business Administration degree and a BA in Economics and Politics from University College Dublin.
Ivan is an entrepreneur with experience in translating early-stage innovations into clinical development programs. As a pharmacologist, he understands the importance of aligning molecular pathways with appropriate therapeutics and diagnostics. He is currently Founder and Managing Director of Eden BioPharma Limited in Dublin. Ivan was also Founder and CEO of Sigmoid Pharma Limited, where he focused on the development of an integrated drug delivery platform within the gastrointestinal tract. As a consultant, he has advised academics and entrepreneurs in setting up companies, developing fundable strategies and building multidisciplinary teams. Ivan obtained his MBA from the Johnson Graduate School of Management at Cornell University in New York and completed his post-doctoral fellowship in developmental biology at the Institut Curie in Paris after receiving a PhD in cancer research and BSc in pharmacology from University College Dublin. He and Ronan are based in Dublin.
“We are committed to supporting new and existing early-stage startups in Europe that are developing innovative clinical diagnostics and life science research tools, as well as therapeutic platforms, digital health initiatives and genomics applications,” said Wouter Meuleman, PhD, Illumina Ventures Partner. “We are excited to have Arnaud, William, Ronan and Ivan join in our efforts.”
About Illumina Ventures
Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina, with the vision to unlock the power of the genome. As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in life science tools, therapeutics, diagnostics, and personal wellness.
For more information, visit illuminaventures.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005179/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Strengthens its Functional Platform to Enter the Fast-Growing Nutraceutical Market with the Acquisition of Sylvestre, a Market Leader in Botanical Extracts Based in Brazil12.3.2026 11:45:00 CET | Press release
The acquisition positions Prodalim to deepen its fast-growing functional beverage solutions offering, accelerate its expansion into the US functional ingredients market, and broaden its presence across emerging markets Prodalim, a global leader in juice and specialty ingredients solutions, announced today the acquisition of Sylvestre, a leading Brazilian producer of botanicals and functional extracts addressing the nutraceutical market. Sylvestre’s existing owners and management team will remain with the company and support its integration into Prodalim’s platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312584318/en/ Founded in 1992 in Brazil, Sylvestre is a trusted supplier of high-quality natural ingredients, specializing in botanical extracts, fruit powders, superfruits, teas, and unique functional plant-based solutions sourced from the rich and diverse Brazilian flora. With a portfolio of more than 200 natural
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 202612.3.2026 11:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Stifel 2026 Virtual CNS Forum, from March 17-18, 2026, and will participate in a fireside chat on March 18, 2026, at 10:30am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our
WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN12.3.2026 11:00:00 CET | Press release
The new WHOOP x SR_A collection includes bespoke, performance-driven WHOOP bands, apparel and outerwear WHOOP, the human performance company, today announces that the first limited-edition collection drop of PROJECT TERRAIN, the multi-year collaboration between WHOOP and Samuel Ross MBE via SR_A, is now available for purchase. The debut collection introduces a technical garment system engineered for movement across environments - redefining the city as a modern training ground for daily performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312513358/en/ WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN PROJECT TERRAIN marks a first for WHOOP, featuring reimagined executions of WHOOP bands, elevated WHOOP Body apparel, and the company’s first entry into technical outerwear. Designed as a unified system, each piece integrates the WHOOP device intentionally and visibly, transf
NAFFCO Group and Verona Shelters Launch Strategic Joint Venture to Scale Civil and Military Shelter Production Globally12.3.2026 10:56:00 CET | Press release
NAFFCO Group has entered into a Joint Venture Agreement with Verona Shelters to form a strategic partnership dedicated to developing and manufacturing advanced civil defense and military shelter solutions in the United Arab Emirates. The partnership significantly expands global production capacity for protective shelter infrastructure at a time when governments and critical industries are strengthening resilience and civil preparedness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312010187/en/ Left: Verona Shelters: Eng. Shaikha Ali Rashed Al Kaabi, (MD UAE) and Mikko Lahtonen, (Executive Director Middle-East); Naffco Group: Eng. Khalid Al-Khatib (CEO); Mr. Ahmed Khalid Al-Khatib, (Group Managing Director); Mr.Ali Khalid Al-Khatib, (Group Managing Director); Ms.Nour Alyazji, (Business Development Director) The collaboration combines NAFFCO’s global leadership in safety engineering and large-scale manufacturing with Ver
Smiths Detection Celebrates Sale of its 2,000th HI-SCAN 6040 CTiX 3D X-ray Scanner12.3.2026 10:00:00 CET | Press release
Major milestone reinforces Smiths Detection’s position as the world’s most trusted provider of advanced screening solutions, deployed at more than 100 airports Smiths Detection, a global leader in threat detection and screening solutions, today announces the sale of its 2,000th HI-SCAN 6040 CTiX, an industry-leading 3D X-ray scanner with high-resolution 3D computed tomography images and intelligent AI-driven automatic detection capabilities. The HI-SCAN 6040 CTiX is deployed across over 100 airports in Europe, Asia-Pacific, the Middle East and the Americas. Operational experience across these regions has demonstrated consistent benefits for airports and passengers alike. Fewer false alarms mean faster, more reliable screening, and as threat profiles change, the technology keeps pace, strengthening security resilience over time. Meanwhile, in eligible locations, passengers no longer need to remove laptops or liquids from their bags, a small change that has a real impact on congestion at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom